World alzheimer day

Why in the news?

  • Two new drugs, Lecanemab (Leqembi) and Donanemab (Kisunla), have emerged as the first treatments capable of slowing Alzheimer’s progression.
  • Developed by U.S. pharma companies Biogen, Eisai, and Eli Lilly, they represent a significant milestone after decades of research.

Highlights of the Controversy Surrounding the Drugs:

  • Despite their potential, the drugs have sparked controversy within the medical community.
  • Supporters, like British biologist John Hardy, believe the treatments mark a crucial turning point in Alzheimer’s research.
  • Critics, like Rob Howard from University College London, argue the drugs raise “false and unrealistic hopes” for patients and families.

Effectiveness and Global Response

  • Both drugs show limited effectiveness, reducing cognitive decline by around 30% in patients with early-stage Alzheimer’s.
  • The global response is mixed, with different countries adopting varying stances on their approval.
  • Regardless of the controversy, these drugs are recognized as the most effective treatments available for Alzheimer’s, though their impact remains modest.

About the World Alzheimer’s Day 2024:

  • Date: September 21, 2024
  • Purpose: Raise awareness about Alzheimer’s disease, reduce stigma, and support early diagnosis and care.
  • Theme: “Time to Act on Dementia, Time to Act on Alzheimer’s”
  • Organised by: Alzheimer’s Disease International (ADI), WHO
  • Target Audience: General public, caregivers, healthcare professionals, policymakers
  • Activities: Awareness campaigns, educational events, fundraising, community support programs

Alzheimer’s Disease Facts:

  • What is Alzheimer’s?: A progressive neurological disorder causing memory loss, cognitive decline, and loss of ability to perform daily tasks.
  • Risk Factors: Age (65+), genetics, lifestyle (lack of exercise, poor diet), and vascular issues (hypertension, diabetes).
  • Global Impact: 55 million people globally suffer from dementia, 70% due to Alzheimer’s; the number could reach 139 million by 2050.

Associated Article:

https://universalinstitutions.com/upsc-essentials-alzheimer-disease/